Has the FDA inspected Empower Pharmacy? Inspection and warning letter records
Has the FDA inspected Empower Pharmacy?
Yes. FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists 2 entries for Empower Pharmacy: a 503B outsourcing facility in Houston, TX and a 503A pharmacy in Houston, TX, with 7 Form 483s issued from 2020 to Nov 14, 2025 and warning letters dated Oct 15, 2021, Apr 2, 2025 and Sep 18, 2026. FDA’s registered outsourcing facility list (updated Nov 6, 2026) names Empower Clinic Services New Jersey in East Windsor, NJ (not yet inspected) and Empower Pharma in Houston, TX (last inspected Nov 14, 2025, Form 483 issued, action “Response Letter Issued 6/3/2026”).
A Form 483 lists an investigator’s observations and is not a final FDA determination. These records cover all of the facility’s compounding, not only GLP-1 drugs.
Empower Clinic Services, LLC, (dba Empower Pharmacy), Houston, TX (503B)
FDA’s compounding inspections and actions page lists 9 actions for this entry.
| Document | |||
|---|---|---|---|
| Nov 14, 2025 | Form 483 | 483 Issued 11/14/2025 | fda.gov |
| Apr 2, 2025 | Warning letter | Warning Letter Issued 04/02/2025 | FDA copy (archived) |
| Aug 28, 2024 | Form 483 | 483 Issued 08/28/2024 | FDA copy (archived) |
| May 4, 2023 | Regulatory meeting | Regulatory Meeting Held 05/04/2023 | Not linked by FDA |
| Aug 5, 2022 | Form 483 | 483 Issued 08/05/2022 | FDA copy (archived) |
| Oct 15, 2021 | Warning letter | Warning Letter (10/15/2021) | FDA copy (archived) |
| Mar 6, 2020 | Form 483 | 483 Issued 03/06/2020 | FDA copy (archived) |
| Jul 22, 2019 | Untitled letter | Untitled Letter Issued 07/22/2019 | FDA copy (archived) |
| Apr 2, 2019 | FMD-145 letter | FMD-145 Letter Issued 04/02/2019 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.
Empower Clinic Services, LLC, (dba Empower Pharmacy), Houston, TX (503A)
FDA’s compounding inspections and actions page lists 5 actions for this entry.
| Document | |||
|---|---|---|---|
| Sep 18, 2026 | Warning letter | Warning Letter Issued 09/18/2026 | fda.gov |
| Nov 14, 2025 | Form 483 | 483 Issued 11/14/2025 | fda.gov |
| Apr 2, 2025 | Warning letter | Warning Letter Issued 04/02/2025 | fda.gov |
| Oct 4, 2024 | Form 483 | 483 Issued 10/04/2024 | FDA copy (archived) |
| Dec 1, 2023 | Form 483 | 483 Issued 12/01/2023 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.
On FDA’s registered 503B list
- Empower Clinic Services New Jersey, East Windsor, NJ: first registered Jun 10, 2024, last inspection not yet inspected, Form 483 N/A.
- Empower Pharma, Houston, TX: first registered Jul 16, 2016, last inspection Nov 14, 2025, Form 483 Yes.
GLP-1 warning letters and recalls under this name
Empower Clinic Services, LLC dba Empower Pharmacy: 1 GLP-1 warning letter, 0 recall reports.
| Later letters FDA lists | Letter | ||||
|---|---|---|---|---|---|
| Sep 18, 2026 | Empower Clinic Services, LLC dba Empower Pharmacy | CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.
These records share a name. FDA lists each under its own legal name and address, and the records do not say how the entities are related.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA warning letter, Sep 18, 2026
Records last pulled Nov 15, 2026. Every entry links to the original public record.